Literature DB >> 16286021

Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function.

Jeffrey L Browning1, Norm Allaire, Apinya Ngam-Ek, Evangelia Notidis, Jane Hunt, Steven Perrin, Roy A Fava.   

Abstract

The lymphotoxin axis is important for the maintenance of several specialized lymphoid microenvironments in secondary lymphoid tissue. Lymphoid-tissue architecture is highly plastic and requires continual homeostatic signaling to maintain its basal functional state. The cellularity of lymph nodes in adult mice was reduced by systemic blockade of lymphotoxin-beta receptor (LTbeta R) signaling with a soluble decoy receptor both in resting and reactive settings. This reduction in cellularity resulted from greatly impaired lymphocyte entry into lymph nodes due to decreased levels of peripheral lymph node addressing (PNAd) and MAdCAM on high endothelial venules (HEV). LTbeta R signaling was required to maintain normal levels of RNA expression of MAdCAM, and also of PNAd by regulating the expression of key enzymes and scaffold proteins required for its assembly. Thus, the homeostatic maintenance of functional HEV status in adult mice relies largely on LTbeta R signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286021     DOI: 10.1016/j.immuni.2005.10.002

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  114 in total

1.  Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules.

Authors:  Christine Moussion; Jean-Philippe Girard
Journal:  Nature       Date:  2011-11-13       Impact factor: 49.962

2.  Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract.

Authors:  Javier Rangel-Moreno; Damian Carragher; Troy D Randall
Journal:  Inmunologia       Date:  2007

Review 3.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

4.  Lymphotoxin-beta receptor blockade induces inflammation and fibrosis in tolerized cardiac allografts.

Authors:  Y Nakayama; J S Bromberg
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

5.  Parenteral nutrition impairs gut-associated lymphoid tissue and mucosal immunity by reducing lymphotoxin Beta receptor expression.

Authors:  Woodae Kang; F Enrique Gomez; Jinggang Lan; Yoshifumi Sano; Chikara Ueno; Kenneth A Kudsk
Journal:  Ann Surg       Date:  2006-09       Impact factor: 12.969

6.  Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors:  Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

7.  A fourth IkappaB protein within the NF-kappaB signaling module.

Authors:  Soumen Basak; Hana Kim; Jeffrey D Kearns; Vinay Tergaonkar; Ellen O'Dea; Shannon L Werner; Chris A Benedict; Carl F Ware; Gourisankar Ghosh; Inder M Verma; Alexander Hoffmann
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

8.  Lymphotoxin-alpha 1 beta 2 and LIGHT induce classical and noncanonical NF-kappa B-dependent proinflammatory gene expression in vascular endothelial cells.

Authors:  Lisa A Madge; Martin S Kluger; Jordan S Orange; Michael J May
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

Review 9.  Immunoregulation by tumor necrosis factor superfamily member LIGHT.

Authors:  Yugang Wang; Mingzhao Zhu; Mendy Miller; Yang-Xin Fu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens.

Authors:  Javier Rangel-Moreno; Juan E Moyron-Quiroz; Damian M Carragher; Kim Kusser; Louise Hartson; Amy Moquin; Troy D Randall
Journal:  Immunity       Date:  2009-05-07       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.